Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Turcot syndrome 2

Interventions

Etoposide 3Carboplatin 3Paclitaxel 2sintilimab 1pembrolizumab 1olaparib 1ceralasertib 1atezolizumab 1apatinib 1anlotinib 1Topotecan 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
SCLC × sintilimab × Clear all
NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
60 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡